1. Home
  2. |Insights
  3. |Congress Considers Tweaking IT Spending

Congress Considers Tweaking IT Spending

Client Alert | less than 1 min read | 10.17.16

On October 5, the Senate Finance Committee sent a letter to commercial information technology providers requesting information about “whether federal agencies, to the fullest extent possible, incorporate preexisting, commercial and non-developmental IT solutions into their modernization efforts and if not, the barriers to their doing so.” Noting that the federal government spent about $80 billion on IT in FY 2015, the committee requested “recommendations” sent to ITContracting@finance.senate.gov by November 2, 2016, for how competition for IT contracts could be broadened by increased use of commercial contracting procedures and fixed-price contracts or changes to evaluation criteria and source selection factors.

Contacts

Insights

Client Alert | 7 min read | 09.14.26

AI in Life Sciences: Ten Legal Considerations and Risks of AI Use in Drug Discovery and Development

Over the past several years, the biopharmaceutical industry has embraced artificial intelligence and machine learning (AI/ML) in near lockstep with the pace of AI/ML innovations. Today, industry leaders are using AI/ML to, among other things: discover and assess biological pathways, target chemical structures and sequences; design proteins; model pre-clinical and clinical trials; recruit and screen potential patient populations; evaluate clinical trial results and biomarker data; prepare regulatory filings; and manage supply chains. Deployment of new AI/ML models promises extraordinary advances in pharmaceutical development. However, as with any technological and scientific advances, the use of AI/ML also poses substantial legal risks that life sciences companies need to consider and proactively manage. ...

View All Insights